Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data

Abstract

AbstractPurposeHealthcare utilization databases often lack information on glycemic control, a key confounder when studying the safety of antidiabetic treatments, since patients with worse control are channeled to second‐line agents, in particular insulin, versus first‐line agents such as metformin. We evaluated whether adjustment for measured characteristics attains balance in glycemic control when comparing antidiabetic treatment strategies in pregnant women with pregestational type 2 diabetes (T2DM).MethodsIn a US insurance claims database, we identified 3360 women with T2DM pregnant between 2004 and 2015, of whom a subset of 996 had data on hemoglobin A1c (HbA1c) levels. We selected insulin only as the comparator group and used propensity score (PS)‐matching on comorbidities and proxies of diabetes severity, but not on HbA1c, to adjust for confounding. We used standardized differences (st.diff) to assess balance in claims‐based covariates and mean HbA1c (% ± SD) in the subset.ResultsThere were imbalances in claims‐based covariates before PS‐matching, with smaller differences when both treatment strategies included insulin. After PS‐matching, balance was achieved in most claims‐based covariates (st.diff <0.1). Mean HbA1c was similar before and after PS‐matching when both treatments included insulin (e.g., 7.1 ± 1.5 vs. 7.7 ± 1.8 and 7.1 ± 1.5 vs. 7.5 ± 1.7, respectively, for metformin + insulin vs. insulin only). Differences in mean HbA1c remained after PS‐matching when non‐insulin treatments were compared to treatments including insulin (e.g., 6.3 ± 1.1 vs. 7.6 ± 1.7 for metformin only vs. insulin only).ConclusionsBalance in both claims‐based characteristics and glycemic control was attained after restricting the population to women with T2DM and comparing treatment strategies indicated for patients with similar diabetes severity. When comparing treatment strategies with versus without insulin, differences in glycemic control persisted after PS‐matching even when balance was attained for other measured characteristics.